Neuron-specific Humoral and Cellular Immune Correlates of Structural and Functional Brain Connectomics in Neuropsychiatric Lupus

NCT05880121 | Recruiting

• 1 other identifier: GR-2021-12372172
• Study Type: observational
• Target: 200
• Locations: 1 country
• Sites: 1

Brief Summary

Systemic lupus erythematosus (SLE) is the prototype systemic autoimmune disease. Neuropsychiatric SLE (NPSLE) is a major cause of morbidity. Its pathophysiology remains unclear and target autoantigens have not yet been identified. Site- specific autoantigen expression might correlate with imaging abnormalities. Based on existing expertise on the use of peptide/protein arrays and on antigen-specific T cell tracking, we plan to identify new fingerprints and targets for NPSLE. SLE patients +/- NPSLE and healthy subjects will undergo advanced magnetic resonance imaging. Three-dimensional data on structural or functional brain architecture will be integrated with brain transcriptome atlases and candidate antigens for autoreactive autoantibodies and T lymphocytes identified and validated. The evidence will add to current knowledge on NPSLE pathophysiology, provide new multimodal diagnostic tools for better patient care and a platform for innovative, personalized treatments.

Conditions

Systemic Lupus Erythematosus

Outcome Measures

Primary Outcomes (3)

• To detect regional brain functional abnormalities in patients with SLE through advanced magnetic resonance imaging (MRI).

  All study subjects will be assessed at baseline through 3T MRI. Repeat MRI will be performed after at least 12 months or in case of new neuropsychiatric events in all patients with SLE. The MRI protocol will include conventional structural sequences (3D fluid-attenuated inversion recovery \[FLAIR\], 3D T1-weighted inversion recovery prepared gradient echo), advanced structural sequences (diffusion-weighted \[DW\] pulsed-gradient spin-echo \[PSGE\] single-shot echo-planar imaging, optimized for an accurate estimation of the neuriteorientation dispersion and density imaging \[NODDI\] model), and functional MRI sequences acquired in resting-state condition.

  12 months (extensions allowed for existing images before study onset)

• To identify autoantigen-specific circulating antibodies associated with neuropsychiatric morbidity and imaging features in patients with SLE.

  High-throughput peptide and/or protein arrays customised according to the data derived from neuroimaging-annotated transcriptome analyses and/or from previous evidence from immune studies performed in a large multicentre cohort of patients with SLE (ZEUS study: NCT02403115) will be used to define candidate antigen targets for autoantibodies. Serum samples will be collected longitudinally at time of clinical evaluation and neuroimaging and analysed by ELISA.

  12 months (extensions allowed for existing MRI images before study onset)

• To correlate antigen-specific CD4+ T-cell dynamics over time with the spectrum of SLE, NPSLE and associated MRI findings.

  Major histocompatibility complex (MHC) multimers bound to relevant autoepitopes identified through in silico analyses of data from neuroimaging-annotated transcriptome analyses and/or from previous evidence from immune studies performed in a large multicentre cohort of patients with SLE (ZEUS study: NCT02403115) will be used to detect and track antigen-specific CD4+ T-cells. Further characterisation of T-cells will be performed in terms of differentiation and polarisation. In vitro T-cell reactivity assays with relevant autoepitopes will also be performed

  12 months (extensions allowed for existing MRI images before study onset)

Study Arms (2)

systemic lupus erythematosus

Patients with SLE according to the 1997 ACR, 2012 SLICC or 2019 EULAR/ACR criteria will undergo MRI along with neuropsychological tests, rheumatological evaluation and blood sample collection at baseline and after at least 12 months or during a new neuropsychiatric manifestation. In case of existing MRI with compatible features, they will be used as baseline studies.

Diagnostic Test: MRI

healthy controls

Subjects with Charlson's Comorbidity Index=0 with no ongoing chronic therapy and no history of immune-mediated disease will undergo a single MRI study, along with neuropsychological tests and blood sample collection. In case of existing MRI with compatible features, no additional studies will be performed in this cohort.

Diagnostic Test: MRI

Interventions

MRI DIAGNOSTIC_TEST

brain MRI

healthy controls; systemic lupus erythematosus

Eligibility Criteria

• Age: 15 Years+
• Sex: all
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

see above

You may qualify if:

• Patients with SLE
• Diagnosis of SLE according to the ACR 1997, SLICC 2012 or EULAR/ACR 2019 criteria
• age ≥ 18 years (reference centre)
• age 15-17 years (affiliated centre)
• Healthy subjects
• Charlson's Comorbidity Index=0 and no chronic treatment
• age ≥ 18 years (reference centre)
• age 15-17 years (affiliated centre)

You may not qualify if:

• History of T-cell neoplasia
• Active B-cell neoplasia or history of B-cell neoplasia of less than five years
• Contraindications to MRI
• Pregnancy
• Ongoing or past treatment with T-depleting agents
• History of brain cancer
• History of congenital brain disorders
• Cerebral disorders secondary to trauma, toxins or other metabolic or environmental factors unrelated to SLE according to the Investigator's evaluation
• Any other condition conferring excessive physical and psychological risk to the subject according to the Investigator's opinion

Sponsors & Collaborators

• IRCCS San Raffaele: lead
• Istituto Giannina Gaslini: collaborator

Study Sites (1)

IRCCS Ospedale San Raffaele

Milan, Italy

RECRUITING

MeSH Terms

Conditions

Lupus Erythematosus, Systemic

Condition Hierarchy (Ancestors)

Connective Tissue Diseases; Skin and Connective Tissue Diseases; Autoimmune Diseases; Immune System Diseases

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Dr.

Study Record Dates

• First Submitted: May 5, 2023
• First Posted: May 30, 2023
• Study Start: April 30, 2023
• Primary Completion: October 30, 2024
• Study Completion: April 29, 2026
• Last Updated: May 30, 2023

Record last verified: 2023-05

Locations

IT (1)